- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about AZN
Recent news which mentions AZN
Better Buy: Novo Nordisk vs. AstraZeneca
January 04, 2025
From Motley Fool
Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million
January 02, 2025
From Benzinga
Why IonQ Is the Best Quantum Computing Stock to Buy Right Now
December 26, 2024
From Motley Fool
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
December 24, 2024
From Benzinga
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer
December 17, 2024
From Benzinga
3 Unstoppable Stocks to Buy Right Now
December 15, 2024
From Motley Fool
From Benzinga
United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
December 13, 2024
From Benzinga
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
December 11, 2024
From Benzinga
2 No-Brainer Dividend Stocks With Yields Over 3% to Buy in 2025 and Hold for a Decade or Longer
December 09, 2024
From Motley Fool
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
December 06, 2024
From Benzinga
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer
December 06, 2024
From Benzinga
FDA Approves AstraZeneca's Blockbuster Cancer Drug Imfinzi For Aggressive Form Of Lung Cancer
December 05, 2024
From Benzinga
Jim Cramer Prefers FedEx Over This Delivery Giant That 'Screwed Up A Lot Of Holiday Seasons'
December 03, 2024
From Benzinga
From Benzinga
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now
November 21, 2024
From Motley Fool
This AstraZeneca Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
November 20, 2024
From Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
November 15, 2024
From Benzinga
From Benzinga
WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill
November 15, 2024
From Benzinga
From Benzinga
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
November 14, 2024
Tickers
AZN
From Motley Fool
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
November 13, 2024
From Benzinga
AstraZeneca Plc (AZN) Q3 2024 Earnings Call Transcript
November 12, 2024
Tickers
AZN
From Motley Fool
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
November 12, 2024
From Benzinga
Earnings Scheduled For November 12, 2024
November 12, 2024
From Benzinga
The Week Kamala Harris Lost (Nov 4-8), These Large Cap Stocks Lost Big
November 11, 2024
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.